Analyzing Spectral AI (NASDAQ:MDAI) and Vasamed (OTCMKTS:VSMD)

Spectral AI (NASDAQ:MDAI) and Vasamed (OTCMKTS:VSMD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Spectral AI and Vasamed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	0	0	1	0	3.00
Vasamed	0	0	0	0	0.00

Spectral AI currently has a consensus price target of $3.50, indicating a potential upside of 92.31%. Given Spectral AI’s stronger consensus rating and higher possible upside, research analysts clearly believe Spectral AI is more favorable than Vasamed.

Earnings and Valuation

This table compares Spectral AI and Vasamed”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$29.58 million	1.64	-$15.31 million	($0.69)	-2.64
Vasamed	N/A	N/A	N/A	N/A	N/A

Vasamed has lower revenue, but higher earnings than Spectral AI.

Profitability

This table compares Spectral AI and Vasamed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-51.97%	N/A	-8.69%
Vasamed	N/A	N/A	N/A

Insider & Institutional Ownership

67.1% of Spectral AI shares are owned by institutional investors. 30.7% of Spectral AI shares are owned by company insiders. Comparatively, 8.0% of Vasamed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Spectral AI beats Vasamed on 6 of the 8 factors compared between the two stocks.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.

About Vasamed

Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.